Koers Aequus Pharmaceuticals Inc Toronto S.E.
Aandelen
CA0076361033
Farmaceutische producten
Omzet 2022 | 1,38 mln. 1,01 mln. 927K | Omzet 2023 | 255K 186K 171K | Marktkapitalisatie | 3,32 mln. 2,42 mln. 2,23 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -3 mln. -2,19 mln. -2,02 mln. | Nettowinst (verlies) 2023 | -2 mln. -1,46 mln. -1,34 mln. | EV/omzet 2022 | 5,17 x |
Nettoschuld 2022 | 2,49 mln. 1,82 mln. 1,67 mln. | Nettoschuld 2023 | 4,85 mln. 3,54 mln. 3,26 mln. | EV/omzet 2023 | 32 x |
K/w-verhouding 2022 |
-1,45
x | K/w-verhouding 2023 |
-1,12
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 85,32% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anne Stevens
FOU | Founder | - | 01-01-13 |
Douglas Janzen
CEO | Chief Executive Officer | 56 | 03-01-13 |
Ann Fehr
DFI | Director of Finance/CFO | 55 | 22-07-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Douglas Janzen
CEO | Chief Executive Officer | 56 | 03-01-13 |
Marc Lustig
BRD | Director/Board Member | 51 | 15-02-21 |
Director/Board Member | 54 | 18-12-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+42,83% | 748 mld. | |
+34,11% | 598 mld. | |
-5,70% | 356 mld. | |
+18,06% | 325 mld. | |
+4,63% | 283 mld. | |
+17,02% | 245 mld. | |
+9,26% | 211 mld. | |
-4,21% | 209 mld. | |
+2,43% | 166 mld. |